April 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
The FDA has approved a supplemental indication for lumateperone to reduce relapse risk in adults with schizophrenia based on phase 3 randomized withdrawal data.
In a recent study, researchers sought to examine treatment patterns, healthcare utilization, and costs among patients diagnosed with schizophrenia receiving oral therapy vs long-acting injectable...
While patients with schizophrenia are known to have an increased risk of obesity and metabolic disease, knowledge regarding eating behaviors in this patient population is still limited.
Using National Health Insurance claims data from patients with schizophrenia and type 2 diabetes in Taiwan, researchers sought to investigate the prevalence and characteristics of schizophrenia in this...
In the absence of well-grounded recommendations for the treatment of insomnia in schizophrenia patients, researchers conducted a systematic review of 4 studies that examined the effects of various options...
Researchers assessed the risk for type 2 diabetes among more than 1600 patients with schizophrenia who were treated with first- and second-generation antipsychotics.
Cigarette smoking is very common among patients with schizophrenia. New research presented at the American Psychiatric Association’s 2018 Annual Meeting may have pinpointed which patients have the highest...
